Visiting Students and Alumni
narges.nasrollahi@gmail.com
Narges Nasrollahi is a researcher in Molecular Neuroscience, specializing in FUS-mediated targeted delivery and nanobubbles across the BBB. She holds a patent for synthesizing nanobubbles containing biogeneric drugs for targeted delivery with FUS, registered as a PCT.
Her innovative research has garnered significant financial support, including a sabbatical grant to Rome from Iran’s MSRT Organization, as well as multiple grants from the Iran Nanotechnology Innovation Council (INIC), the Iran Vice-Presidency for Science and Technology (ISTI), the Iran National Science Foundation (INSF), Iran National Innovation Fund (INIF), and the National Institute of Genetic Engineering and Biotechnology (NIGEB).
Narges’s outstanding contributions led to her receiving the first-place award at the Phoenix Event organized by the National Elites Foundation. Her project distinguished itself among 500 competing entries, earning her a $20,000 prize. Furthermore, in 2024, she was honored as the Role Model Student at the NIGEB.
CONCLUSION: Exosomes constitute a versatile platform for BBB-crossing drug delivery. By consolidating mechanistic, preclinical, and translational evidence, this review highlights their transformative potential in neurodegenerative disease therapy while outlining limitations and future directions.
Amyloid aggregation of α-synuclein (αSN) protein amplifies the pathogenesis of neurodegenerative diseases (NDs) such as Parkinson's disease (PD). Consequently, blocking aggregation or redirecting self-assembly to less toxic aggregates could be therapeutic. Here, we improve brain-specific nanocarriers using a hybrid of exosomes (Ex) from human umbilical cord mesenchymal stem cells (hUC MSCs) and nanoliposomes containing baicalein (Ex-NLP-Ba) and oleuropein (Ex-NLP-Ole). The hybrids contained both...
The overall success in launching discovered drugs is tightly restricted to the high rate of late-stage failures, which ultimately inhibits the distribution of medicines in markets. As a result, it is imperative that methods reliably predict the effectiveness and, more critically, the toxicity of medicine early in the drug development process before clinical trials be continuously innovated. We must stay up to date with the fast appearance of new infections and diseases by rapidly developing the...
Efficient strategies to promote microvascularization in vascular tissue engineering, a central priority in regenerative medicine, are still scarce; nano- and micro-sized aggregates and spheres or beads harboring primitive microvascular beds are promising methods in vascular tissue engineering. Capillaries are the smallest type and in numerous blood vessels, which are distributed densely in cardiovascular system. To mimic this microvascular network, specific cell components and proangiogenic...
Created by An:Ca © 2025 Tor Vergata University P.I. 02133971008 – C.F. 80213750583
